RBF Capital’s Lifecore Biomedical LFCR Stock Holding History

RBF Capital’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-13,815	Closed	-$73.4K	–	587
2024 Q1	$73.4K	Buy	+13,815	New	+$98.8K	﹤0.01%	539

Other funds holding LFCR

Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

LPAM

Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return

GRIM

Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

325 Capital New York $274M AUM 49.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VWA

Visionary Wealth Advisors O'fallon, Illinois $2.26B AUM 19.48% 1-Year Est. Return

RBF Capital's LFCR Position: Q2 2024 in Review

RBF Capital sold out of Lifecore Biomedical (LFCR) in Q2 2024, closing a stake of 13,815 shares — an estimated $73.4K sold.

RBF Capital first reported a position in LFCR in Q1 2024 and held it in 1 quarter. The position peaked at $73.4K in Q1 2024. 75 funds tracked by Wall St. Rank hold LFCR as of Q2 2024.

RBF Capital reported no remaining Lifecore Biomedical position as of Q2 2024 after selling out during the quarter.
RBF Capital sold 13,815 Lifecore Biomedical shares in Q2 2024, an estimated $73.4K.
RBF Capital first reported a position in Lifecore Biomedical in Q1 2024 and held it in 1 quarter.
RBF Capital's Lifecore Biomedical position peaked at $73.4K in Q1 2024.
75 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2024.

Based on RBF Capital's 13F filing for Q2 2024, filed 14 Aug 2024.